Literature DB >> 21544432

Oligonucleotides complementary to c-myb messenger RNA inhibit growth and induce apoptosis in human Burkitt lymphoma cells.

S Joshi1, A Wu, D Verbik, S Algarra, M Bishop, S Pirruccello, P Iversen, J Jackson, M Kessinger, J Sharp.   

Abstract

A 24-mer (antisense) phosphorothioate oligonucleotide (ODN) corresponding to the codons 2-9 of the c-myb gene was evaluated for its effects on the growth of a human Burkitt lymphoma cell line (Raji) in vitro. Raji cells incubated with different concentrations of c-myb antisense ODN (5-15 mu g/ml) for 24-72 h showed a significant dose-dependent decrease in growth. The same concentrations of control (sense) or scrambled c-myb phosphorothioate ODNs did not inhibit Raji cell growth. The c-myb antisense ODN, but not the control ODNs, significantly decreased c-myb mRNA levels in treated cells as determined by RT-PCR. Additionally, the c-myb antisense ODN induced apoptosis of Raji cells as demonstrated by i) flow cytometry to enumerate the A(o) (apoptotic cell population) population of propidium iodide stained cells; ii) electron microscopy to evaluate the cell morphology; and iii) DNA fragmentation pattern. Thus, an antisense c-myb ODN causes significant growth inhibition of Burkitt lymphoma cells, and one mechanism of growth inhibition is the induction of apoptosis of the lymphoma cells. In addition, antisense c-myb ODN did not reduce CFU-GM or BFU-e colony-forming ability of normal hematopoietic stem/progenitor cells. Because the inhibition is sequence-specific and Burkitt lymphoma cell selective, evaluation of the therapeutic effects of c-myb antisense ODN against Burkitt lymphoma is warranted.

Entities:  

Year:  1996        PMID: 21544432     DOI: 10.3892/ijo.8.4.815

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity.

Authors:  P Salomoni; D Perrotti; R Martinez; C Franceschi; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

2.  FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.

Authors:  Franziska Gehringer; Stephanie E Weissinger; Lotteke Jym Swier; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Cancers (Basel)       Date:  2019-09-25       Impact factor: 6.639

3.  Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.

Authors:  Franziska Gehringer; Stephanie Ellen Weissinger; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Leukemia       Date:  2019-11-12       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.